Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya BioSciences, Inc. - Common Stock (NQ: AKYA )

2.440 +0.030 (+1.24%)
Streaming Delayed Price Updated: 1:53 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,769
Open 2.380
Bid (Size) 2.430 (2)
Ask (Size) 2.450 (2)
Prev. Close 2.410
Today's Range 2.318 - 2.450
52wk Range 1.880 - 6.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
From Akoya Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-48.95%
-48.95%
1 Month
+15.09%
+15.09%
3 Month
-10.29%
-10.29%
6 Month
-5.43%
-5.43%
1 Year
-51.87%
-51.87%

More News

Read More
A Closer Look at 4 Analyst Recommendations For Akoya Biosciences
Via Benzinga
Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Akoya Biosciences Reports Third Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
From Akoya Biosciences, Inc.
Via GlobeNewswire
AKYA Stock Earnings: Akoya Biosciences Meets EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
AKYA Stock Earnings: Akoya Biosciences Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
From Akoya Biosciences, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.